Novo Nordisk defends diabetes drug pricing

Organisation: Position: Deadline Date: Location:

Danish diabetes drug maker Novo Nordisk has defended its pricing of diabetes drugs after facing allegations of pricing collusion by US senators.

“In order to get on the (product lists), which receive subsidies by the different insurance companies, we need to offer rebates,” Mike Rulis, senior vice president of corporate communications is quoted in

“In order to get on the (product lists), which receive subsidies by the different insurance companies, we need to offer rebates,” Mike Rulis, senior vice president of corporate communications is quoted in Reuters Health as saying. “Those rebates have increased over the years, as well as list prices.”

The world’s largest insulin maker gets around half its revenue in the US, but prices have been squeezed by pharmacy benefit managers (PBMs) who administer drug benefits and negotiate rebates for employers and health plans.

US Senator Bernie Sanders and Representative Elijah Cummings have called on antitrust regulators to investigate whether insulin and diabetes drugs makers such as Sanofi SA, Eli Lilly and Co and Novo Nordisk have colluded to set drug prices on the US market.
Last year Novo Nordisk offered an average rebate of 55% on its products in the US, Rulis said, but could not elaborate further due to trade confidentiality.

Some US consumers have experienced price increases, while others have not, he said.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.